Trial
NCT02706353
APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
M.D. Anderson Cancer Center
Collaborators
Apexigen America, Inc.; Pyxis Oncology
Condition
Melanoma
Intervention
APX005M
Why stopped
\<75% participant accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-21